Craig-Hallum analyst Alex Nowak lowered the firm’s price target on Exact Sciences to $88 from $106 and keeps a Buy rating on the shares following quarterly results. The momentum of screening and precision oncology for Exact Sciences continued in Q3, with revenue and guidance raised and pipeline commentary largely confirmatory, the firm notes. Craig-Hallum thinks there is some conservatism in store on management’s Q4 guide and anticipates the company could report a strong pre-announcement in early January, even despite the holiday dynamics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EXAS:
- Exact Sciences price target lowered to $95 from $110 at Jefferies
- Exact Sciences price target lowered to $100 from $120 at TD Cowen
- Exact Sciences sees FY23 revenue $2.476B-$2.486B, consensus $2.46B
- Exact Sciences reports Q3 EPS 0c, consensus (49c)
- Exact Sciences Announces Third-Quarter 2023 Results